How the FDA will decide if a coronavirus vaccine is safe and effective

The Food and Drug Administration has received some criticism amid the coronavirus pandemic for rushing approval on some medications, but the agency is expected to assure everyone Tuesday that it "will not reduce its standards or cut corners in its review to approve a vaccine" despite moving at unprecedented speed to do so, The Wall Street Journal reports.
FDA Commissioner Stephen Hahn is expected to discuss the agency's guidance for vaccine approval in Congressional testimony Tuesday. Per the Journal, the FDA won't give a candidate the green light unless the manufacturer "clearly" demonstrates its safety and effectiveness through a clinical study, and the production of antibodies in patients' bloodstream alone won't lead to approval since it's still unknown what levels of antibodies provide protection.
The Journal's report doesn't contain much more detail beyond about what warrants approval, but it does reveal the FDA's watch won't end after a vaccine hits the market. Instead, vaccine makers will reportedly be required to monitor recipients for a year after treatment since "post-market studies" may be necessary to "further assess known or potential serious risks." Read more at The Wall Street Journal.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
5 exclusive cartoons about Trump and Putin negotiating peace
Cartoons Artists take on alternative timelines, missing participants, and more
By The Week US Published
-
The AI arms race
Talking Point The fixation on AI-powered economic growth risks drowning out concerns around the technology which have yet to be resolved
By The Week UK Published
-
Why Jannik Sinner's ban has divided the tennis world
In the Spotlight The timing of the suspension handed down to the world's best male tennis player has been met with scepticism
By The Week UK Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published